NCT02868268Active, not recruiting
Neuroblastoma Precision Trial
N2015-01: Neuroblastoma Precision Trial
Source: ClinicalTrials.gov · Last updated 23 Mar 2026
Brief summary (registry, in English)
This proposal sets forth the platform for a Precision Medicine clinical trial through the New Approaches to Neuroblastoma Therapy (NANT) consortium. The plan is to utilize NANT's established multi-institutional infrastructure and Translational Genomics Research Institute GEM sequencing platform for acquisition and gene panel sequencing of relapsed biological specimens in relapsed/refractory neuroblastoma (rNB) including those obtained from the bone, bone marrow or soft tissue. Our primary aim is to identify subgroups of rNB patients who have potentially targetable genetic (ALK, MAPK pathway, Metabolic-related genes) and/or immunologic (tumor-associated macrophage infiltration and/or programmed death ligand \[PD-L1\] expression) biomarkers in rNB. Additional potential novel biomarkers will also be evaluated and reported in this cohort of patients.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 93 (actual)
- First submitted
- 3 Jun 2016
- Start date
- 22 Aug 2016
- Primary completion date
- Dec 2026
- Lead sponsor
- New Approaches to Neuroblastoma Therapy Consortium
- Diseases
- Neuroblastoma, Childhood cancers
- NCT number
- NCT02868268
What you commit to
- Study type: Observational
- Participants enrolled: 93
- From 22 Aug 2016 to the primary completion date, Dec 2026
- 11 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with disease of any major organ system that would compromise their ability to withstand biopsy procedures of soft tissue, bone and/or bone marrow.
Other
- Patients who enroll and successfully receive a NANT Precision Report may not re-enroll at a future time.
- Patient declines participation in NANT 2004-05, the NANT Biology Study.
Who the study is looking for
- Patients must be ≥ 1 year and ≤ 30 years of age at study registration
- Patients must have had a diagnosis of neuroblastoma either by histological verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased urinary catecholamines.
- Patients must have a history of high-risk neuroblastoma according to
- COG risk classification at the time of study registration. Patients must have at least one of the following: Recurrent/progressive disease, Refractory disease, Persistent disease
- Patient must be willing to undergo a clinically indicated biopsy and meet at least one of the following requirements: Bone biopsy, Soft tissue biopsy, Bone marrow biopsy and aspirate
- Patients must not be receiving any other anti-cancer agents or radiotherapy during the interval
Age in the registry: 1 year to 30 years · Sex: All · Does not accept healthy volunteers
Sites (11)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| C S Mott Children's Hospital Coordinator of this site? Confirm its status | Ann Arbor | United States | Unknown status |
| Children's Healthcare of Atlanta Coordinator of this site? Confirm its status | Atlanta | United States | Unknown status |
| Children Hospital of Colorado Coordinator of this site? Confirm its status | Aurora | United States | Unknown status |
| Childrens Hospital Boston, Dana-Farber Cancer Institute. Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
| University of North Carolina Coordinator of this site? Confirm its status | Chapel Hill | United States | Unknown status |
| Children's Memorial Hospital - Chicago Coordinator of this site? Confirm its status | Chicago | United States | Unknown status |
| Cincinnati Children's Hospital Medical Center Coordinator of this site? Confirm its status | Cincinnati | United States | Unknown status |
| Cook Children's Healthcare System Coordinator of this site? Confirm its status | Fort Worth | United States | Unknown status |
| Children's Hospital Los Angeles Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
| UCSF Helen Diller Family Comprehensive Cancer Center Coordinator of this site? Confirm its status | San Francisco | United States | Unknown status |
| Children's Hospital and Regional Medical Center - Seattle Coordinator of this site? Confirm its status | Seattle | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.